Charles Schwab Investment Management Inc. Has $13.35 Million Stake in Phreesia, Inc. $PHR

Charles Schwab Investment Management Inc. raised its stake in Phreesia, Inc. (NYSE:PHR) by 5.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 522,384 shares of the company’s stock after buying an additional 28,936 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.89% of Phreesia worth $13,352,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. acquired a new position in Phreesia in the first quarter valued at about $1,623,000. Deutsche Bank AG lifted its stake in Phreesia by 95.9% in the fourth quarter. Deutsche Bank AG now owns 57,297 shares of the company’s stock valued at $1,442,000 after buying an additional 28,047 shares during the period. Bessemer Group Inc. lifted its stake in Phreesia by 23.2% in the first quarter. Bessemer Group Inc. now owns 47,758 shares of the company’s stock valued at $1,222,000 after buying an additional 8,978 shares during the period. SG Americas Securities LLC acquired a new position in Phreesia in the first quarter valued at about $462,000. Finally, CWM LLC lifted its stake in Phreesia by 994.9% in the first quarter. CWM LLC now owns 4,040 shares of the company’s stock valued at $103,000 after buying an additional 3,671 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

Insiders Place Their Bets

In other Phreesia news, Director Mark Douglas Smith sold 7,000 shares of the business’s stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $29.00, for a total value of $203,000.00. Following the completion of the sale, the director owned 37,353 shares of the company’s stock, valued at $1,083,237. The trade was a 15.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Evan Roberts sold 1,892 shares of the stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $26.89, for a total transaction of $50,875.88. Following the transaction, the chief operating officer owned 772,915 shares in the company, valued at approximately $20,783,684.35. The trade was a 0.24% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,882 shares of company stock worth $1,513,007. 5.50% of the stock is currently owned by insiders.

Phreesia Price Performance

Phreesia stock opened at $29.7760 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02. The stock’s 50 day moving average is $27.49 and its 200-day moving average is $26.41. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -40.24 and a beta of 0.71.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. The firm had revenue of $115.94 million for the quarter, compared to analysts’ expectations of $115.00 million. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%.The company’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.05) EPS. Phreesia has set its FY 2026 guidance at EPS. Equities research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Wall Street Analysts Forecast Growth

PHR has been the topic of several analyst reports. DA Davidson raised Phreesia to a “strong-buy” rating in a research note on Tuesday, July 22nd. Canaccord Genuity Group reduced their price objective on Phreesia from $35.00 to $34.00 and set a “buy” rating for the company in a research report on Thursday, May 29th. Wall Street Zen upgraded Phreesia from a “hold” rating to a “buy” rating in a report on Sunday, June 1st. Truist Financial lifted their target price on Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, May 29th. Finally, KeyCorp upped their price target on Phreesia from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $32.27.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.